drugset / Trial / NCT04315987
NestaCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia
Phase 2
Completed
90 enrolled
Azidus Brasil
Cellavita Pesquisa Científica Ltda · collabHospital Vera Cruz · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is phase II study to assess the efficacy of NestaCell® (mesenchymal stem cell) to treat severe COVID-19 pneumonia.
Timeline
- Start
- 2020-06-30
- Primary completion
- 2021-02-28
- Completion
- 2021-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mesenchymal stem cell | Cell therapy | 2e+07 cells | Intravenous |